The lancet. Diabetes & endocrinologyAdultAgedFemaleHumansMale
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.
Filip K Knop, George Kunos, Dror Dicker, Jean-Sebastien Paquette, Louis Aronne, Ofir Frenkel, Thomas Holst-Hansen, Karine Lalonde, Jisoo Lee, Glenn Crater, trial investigators
Published: 202510.1016/S2213-8587(25)00216-5
Abstract
BACKGROUND: Monlunabant, a novel cannabinoid receptor 1 (CB1R) inverse agonist, has shown encouraging weight loss efficacy and tolerability. We aimed to evaluate the efficacy and safety of monlunabant in individuals with obesity and metabolic syndrom…
Preview only. Read the full abstract at the source